NewHavenBIZ

www.HartfordBusiness.com • May 25, 2020 • Hartford Business Journal 7 LEADERSHIP IN A TIME OF CRISIS 215 Church Street, New Haven, CT 06510 I BiohavenPharma.com I p: (203) 404 0410 As our New Haven community and nation navigates the current health crisis, Biohaven's relentless compassion for patients guides the actions we are taking to alleviate disabil- ity, improve physical and emotional well-being, and offer cer- tainty to those who need it most. Biohaven remains steadfast in our commitment to patients who count on us to continue to deliver important therapies for other medical conditions during these difficult and uncertain times. We understand that right now many people are coping with increased stress and anxiety. This can trigger heightened migraine attacks during a time when access to medication is hampered by social distancing that is redefining doctor- patient interactions. To provide the relief that will help people with migraine function normally during these hectic times, we moved with urgency to increase patient accessibility to NURTEC™ ODT (rimegepant), our newly approved drug for the acute treatment of migraine in adults. With more people now turning to telemedicine to access medical care and pre- scriptions, we accelerated the availability of NURTEC ODT on the COVE telemedicine network (www.nurtec.com). Patients can schedule an evaluation with a doctor on the telemedicine site and, if appropriate, get a prescription for NURTEC ODT delivered to their home or local pharmacy. We are also offer- ing $0 copay cards to commercially-insured patients for the remainder of 2020. These are important steps that will ease the strain on people with migraine and enable them to focus on what is most important — staying safe and healthy. As a company dedicated to science and medicine, Biohaven also recognizes the critical importance of our ongoing drug discovery efforts to patients with severe neurologic disorders, such as Alzheimer's Disease, Spinocerebellar Ataxia, Multiple System Atrophy, and other conditions. We know that countless patients are eagerly awaiting the results of our ongoing clini- cal studies of potential new treatments. Patients in our trials and clinical sites have worked courageously to help advance Biohaven's scientific discoveries. They cannot wait and neither will we. That is why our research and development team has been working to ensure that our ongoing studies are complet- ed despite the challenges of the COVID-19 health emergency. With patients at the center of our business, we knew it was critical to accelerate our implementation plan to ensure no disruptions to patient access. Biohaven is an agile, entrepre- neurial organization with a culture to identify innovative ways to adapt technology and continue our mission. We also have continued our research operations, including work- ing with the U.S. Food and Drug Administration to initiate a Phase 2 study of vazegepant, an intranasal, calcitonin gene- related peptide (CGRP) receptor antagonist, as a potential treatment of COVID-19 infection associated pulmonary com- plications. I could not be prouder of our entire team and the creative resolve they have shown to ensure that Biohaven's focus on patients never wavers. On behalf of the Biohaven team, I would like to send my deepest gratitude and appreciation to the healthcare profes- sionals on the frontlines of the pandemic who are rising to the challenge every day to help the most vulnerable among us. You are heroes. We are proud to be your colleagues in the healthcare industry. We are all in this together. Vlad Coric, M.D. Chief Executive Officer Biohaven Pharmaceuticals

• Cover